Sepsis Market Insights Gain Momentum with Expanding Pipeline and Investment Potential by 2034 - DelveInsight

DelveInsight's "Sepsis Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To know in detail about the Sepsis market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Sepsis Market Forecast- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Key Facts of the Sepsis Market Report:

• In April 2025, Vivacelle Bio announced that a study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia. Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs.
• In March 2025, Accelerate Diagnostics announced the submission of its Accelerate WAVETM system and positive blood culture gram-negative test kit to the FDA for 510(k) clearance. The WAVE system offers rapid antimicrobial susceptibility testing (AST) from positive blood cultures and bacterial isolate colonies, providing accurate results in about 4.5 hours to enable same-shift targeted antimicrobial therapy for patients with serious infections.
• Among the 7MM, the United States accounted for the highest Sepsis market share in 2023, representing above 55% of the Sepsis population.
• In EU4 and the United Kingdom, Germany accounted for the highest number of incident cases in 2023.
• Approximately 57% of all cases were sepsis without organ dysfunction, followed by septic shock (24%) and severe sepsis (18%) in the United States in 2023.
• The majority of the patient pool was male across the 7MM, whereas in the US female population dominated the Sepsis incident pool.
• Lung infection, UTI infection, gut infection, and skin infection are the leading four infection sites in patients with sepsis, accounting for approximately 43%, 30%, 13%, and 13%, respectively.
• Key Sepsis Companies: La Jolla Pharmaceuticals, ReCode Therapeutics, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., and others.
• Key Sepsis Therapies: GIAPREZA, Onoact Injection, VBI-S, Nangibotide, ALLOCETRA, enibarcimab, and others.
• The Sepsis Therapeutics Market in the 7MM is expected to surge due to rising Sepsis incidence population, technological advancements, increased funding for new drug development, and launching of multiple promising emerging therapies.

Get a Free sample for the Sepsis Market Forecast, Size & Share Analysis Report - https://www.delveinsight.com/sample-request/sepsis-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Sepsis Overview

Sepsis is a life-threatening organ dysfunction that results from the body's response to infection. If not recognized early and managed promptly, it can lead to septic shock, multiple organ failure, and death. Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality. The initial evaluation of a patient with sepsis includes medical history, physical examination, and clinical symptoms, along with the detection of biomarkers such as C reactive protein and procalcitonin, which are crucial elements for early diagnosis of sepsis and the timely establishment of appropriate clinical management.

Sepsis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the incident patient pool and future trends.

Sepsis Epidemiology Segmentation:

The Sepsis market report provides epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Sepsis Incidence Cases
• Sepsis Gender-specific Incidence Cases
• Sepsis Severity-specific Incidence Cases
• Origin-specific Sepsis Incidence Cases

Download the report to understand which factors are driving Sepsis epidemiology trends @ Sepsis Epidemiology Forecast- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Sepsis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Sepsis market or expected to get launched during the study period. The analysis covers Sepsis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sepsis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Sepsis market share @ Sepsis Treatment Landscape- https://www.delveinsight.com/sample-request/sepsis-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Sepsis Therapies and Key Companies

Marketed Therapies:

• GIAPREZA (angiotensin II): La Jolla Pharmaceuticals/Innoviva Specialty Therapeutics
• Onoact Injection (Landiolol hydrochloride): Ono Pharmaceuticals

Emerging Therapies:

• VBI-S: Vivacelle Bio
• Nangibotide: Inotrem
• ALLOCETRA: Enlivex Therapeutics
• Enibarcimab: Adrenomed

Sepsis Market Drivers

• Rising Global Incidence of Sepsis, driven by aging populations, antimicrobial resistance, and hospital-acquired infections, significantly boosting demand for effective diagnostic and therapeutic interventions.
• Growing Awareness and Early Diagnosis Initiatives, with government bodies and healthcare organizations focusing on raising awareness about early identification and management of sepsis.
• Technological Advancements in Diagnostics and Therapeutics, including rapid diagnostic technologies, point-of-care testing, and development of novel therapies and immunomodulators.
• Regulatory Support and Incentives for Novel Therapies, with FDA and EMA offering fast-track designations and other incentives to encourage innovation in sepsis therapeutics.
• Increased Funding for Drug Development and Clinical Trials, supporting research and development of targeted therapies.

Sepsis Market Barriers

• Complex Disease Pathophysiology, involving a wide array of causative agents and varying individual immune responses, complicating treatment standardization.
• High Treatment and Care Costs, which may limit access and reimbursement in certain regions.
• Delayed or Underdiagnosis, particularly in low-resource settings, restricting timely treatment adoption.
• Limited Availability of Approved Disease-Specific Therapies, with most treatments focused on symptom management rather than disease modification.

Scope of the Sepsis Market Report

• Study Period: 2020-2034
• Forecast Period: 2024-2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Sepsis Companies: La Jolla Pharmaceuticals, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., and others
• Key Sepsis Therapies: GIAPREZA, Onoact Injection, VBI-S, Nangibotide, ALLOCETRA, enibarcimab, and others
• Sepsis Therapeutic Assessment: Sepsis current marketed and Sepsis emerging therapies
• Sepsis Market Dynamics: Sepsis market drivers and Sepsis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Sepsis Unmet Needs, KOL's views, Analyst's views, Sepsis Market Access and Reimbursement

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.